arrow
T

Tuna Mutis

Cancer Center Amsterdam
H指数:61
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Dual targeting of BCMA and GPRC5D with the trispecific antibody ramantamig addresses antigenic heterogeneity in myeloma

双靶向BCMA和GPRC5D的trispecific antibody ramantamig解决了骨髓瘤中的抗原异质性

2026-10-080
OAAI
Monocyte-mediated metabolic rewiring via CD31-CD38 interactions promotes growth and drug-resistance in multiple myeloma

单核细胞介导的代谢重编程通过CD31-CD38相互作用促进多发性骨髓瘤的生长和药物抗性

2026-04-160
OAAI
Immune biomarkers of increased infection risk in multiple myeloma

多发性骨髓瘤中感染风险增加的免疫生物标志物

Blood
IF23.1
2026-04-011
PRE
Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma

帕博利珠单抗替代给药方案在多发性骨髓瘤治疗中的药代动力学和药效动力学评价

2025-11-030
OAAI
Cytoskeletal dynamics and mitochondrial rearrangements drive cell fate upon antibody-induced complement activation in DLBCL

细胞骨架动力学和线粒体重排驱动弥漫大B细胞淋巴瘤中抗体诱导的补体激活后的细胞命运

2025-10-060
OA
Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first-line therapy irrespective of frailty levels

老年新诊断多发性骨髓瘤患者的免疫特征与一线治疗的生存结局相关,且与脆弱性水平无关。

2025-10-050
OAAI
A T-cell-based metric of immune age predicts outcomes in elderly myeloma patients receiving daratumumab-based therapy

基于T细胞的免疫年龄指标可预测接受达雷木单抗为基础疗法的老年骨髓瘤患者的结局

Blood
IF23.1
2025-08-210
PRE
Immunosuppressed Tumor Microenvironment in MYC-Rearranged High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas, Not Otherwise Specified

MYC重排的高级别B细胞淋巴瘤与未特别指明的弥漫性大B细胞淋巴瘤相比的免疫抑制性肿瘤微环境

BLOOD
IF23.1
2024-11-050
PRE
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity
2023-07-0111
OAAI
NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma
2023-05-0117
OAAI
Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence

结合CAR和嵌合共刺激受体可增强T细胞对低抗原密度的敏感性并促进持久性

2021-12-0862
OA
Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma

达雷妥尤单抗联合全反式维甲酸治疗复发/难治性多发性骨髓瘤的疗效和安全性

2021-12-0625
OAAI
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma

GPRC5DxCD3双特异性抗体talquetamab在多发性骨髓瘤中的临床前活性和反应决定因素

2021-04-23101
OA